Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06427694
Other study ID # IVORY-FINALE (A096877)
Secondary ID 339102
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2024
Est. completion date February 11, 2030

Study information

Verified date June 2024
Source Cambridge University Hospitals NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The preceding IVORY trial (NCT04241601) has completed. As atherosclerosis and its complications are driven by inflammation the investigators hypothesise that treatment with low-dose IL2 may reduce adverse cardiovascular outcomes compared to placebo. In this follow-up study, the investigators aim to collect cardiovascular clinical outcome data for patients who completed the IVORY clinical trial and will look at major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, resuscitated cardiac arrest, ischaemic stroke, or unplanned coronary revascularization. In addition, data on adverse events such as all cause death, haemorrhagic stroke, new atrial fibrillation, ventricular arrhythmias, hospitalisation due to cardiovascular causes (e.g. stable and unstable angina, TIAs, heart failure), amputations and revascularisation due to peripheral vascular disease.


Description:

A heart attack occurs when there is reduced blood flow to heart muscle cells which results from narrowings or blockages in walls of blood vessels supplying the heart, due to fatty deposits and inflammatory cells that build up over time. This build-up leads to heart muscle damage called a heart attack. The immune system plays an important role in both the development of the narrowings and the damage to the heart muscle during a heart attack. Studies have shown that there is a lower level of protective immune cells called regulatory T-cells (Tregs) in heart attack patients. Increasing the number of circulating Tregs may have a direct effect in reducing the inflammation in arteries, preventing further narrowings in blood vessels and improving heart muscle function. Aldesleukin, also known as interleukin-2 (IL2), is a medicine that stimulates the production of Treg cells when given at low doses. The effectiveness of IL2 in influencing the immune system was tested in a phase 2 trial, IVORY. Participants were recruited to the IVORY trial following a sudden narrowing/blockages in walls of blood vessels to the heart resulting in a heart attack (Acute Coronary Syndrome (ACS)). Participants were randomised to receive either low dose IL2 or placebo, researchers and participants were blinded to the treatment allocation. Participants underwent two PET/CT (Positron emission tomography-computed tomography) scans to observe change of inflammation in the blood vessels from baseline between the two trial groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date February 11, 2030
Est. primary completion date April 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Participants who completed the full per-protocol treatment regime of low-dose IL2 or placebo having attended the final dosing visit in the IVORY trial. IVORY patients who previously consented to have their medical records inspected in the IVORY trial and who have already passed away at the commencement of IVORY-FINALE will also be included in analyses Exclusion Criteria: - Patients who decline participation - Patients who did not consent to being contacted about future research - Patients who were withdrawn from the IVORY trial for any reason

Study Design


Intervention

Drug:
Aldesleukin
IL2 antagonist
Dextrose 5% in water
matched placebo to active

Locations

Country Name City State
United Kingdom Addenbrooke's Hospital Cambridge Cambridgeshire

Sponsors (1)

Lead Sponsor Collaborator
Cambridge University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major adverse cardiovascular outcomes Number of major adverse cardiovascular outcomes 1 year from when initially dosed in preceding IVORY trial
Primary Major adverse cardiovascular outcomes Number of major adverse cardiovascular outcomes 2 years from when initially dosed in preceding IVORY trial
Primary Major adverse cardiovascular outcomes Number of major adverse cardiovascular outcomes 5 years from when initially dosed in preceding IVORY trial
Secondary Death due to cardiovascular causes Number of deaths due to cardiovascular causes comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Deaths due to cardiovascular causes comparing IL2 to placebo Number of deaths due to cardiovascular causes comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Deaths due to cardiovascular causes comparing IL2 to placebo Number of deaths due to cardiovascular causes comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Resuscitated cardiac arrests comparing IL2 to placebo Numbers of resuscitated cardiac arrests comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Resuscitated cardiac arrests comparing IL2 to placebo Numbers of resuscitated cardiac arrests comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Resuscitated cardiac arrests comparing IL2 to placebo Numbers of resuscitated cardiac arrests comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Non-fatal MI (including NSTEMI and STEMI) comparing IL2 to placebo Number of non-fatal MI (including NSTEMI and STEMI) comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Non-fatal MI (including NSTEMI and STEMI) comparing IL2 to placebo Number of non-fatal MI (including NSTEMI and STEMI) comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Non-fatal MI (including NSTEMI and STEMI) comparing IL2 to placebo Number of non-fatal MI (including NSTEMI and STEMI) comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Ischaemic strokes comparing IL2 to placebo Number of ischaemic strokes comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Ischaemic strokes comparing IL2 to placebo Number of ischaemic strokes comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Ischaemic strokes comparing IL2 to placebo Number of ischaemic strokes comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Unplanned coronary vascularisations comparing IL2 to placebo Number of unplanned coronary vascularisations comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Unplanned coronary vascularisations comparing IL2 to placebo Number of unplanned coronary vascularisations comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Unplanned coronary vascularisations comparing IL2 to placebo Number of unplanned coronary vascularisations comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Hospitalisations due to cardiovascular causes comparing IL2 to placebo Number of hospitalisations due to cardiovascular causes comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Hospitalisations due to cardiovascular causes comparing IL2 to placebo Number of hospitalisations due to cardiovascular causes comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Hospitalisations due to cardiovascular causes comparing IL2 to placebo Number of hospitalisations due to cardiovascular causes comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary All-cause deaths comparing IL2 to placebo Number of all-cause deaths comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary All-cause death comparing IL2 to placebo Number of all-cause deaths comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary All-cause death comparing IL2 to placebo Number of all-cause deaths comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Hospitalisations due to symptoms from heart failure (incl admission due to pulmonary oedema and congestive heart failure) comparing IL2 to placebo Number of hospitalisations due to symptoms from heart failure (incl admission due to pulmonary oedema and congestive heart failure) comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Hospitalisations due to symptoms from heart failure (incl admission due to pulmonary oedema and congestive heart failure) comparing IL2 to placebo Number of hospitalisations due to symptoms from heart failure (incl admission due to pulmonary oedema and congestive heart failure)comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Hospitalisations due to symptoms from heart failure (incl admission due to pulmonary oedema and congestive heart failure) comparing IL2 to placebo Number of hospitalisation due to symptoms from heart failure (incl admission due to pulmonary oedema and congestive heart failure) comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Revascularisations for peripheral vascular disease comparing IL2 to placebo Number of revascularisations for peripheral vascular disease comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Revascularisations for peripheral vascular disease comparing IL2 to placebo Number of revascularisations for peripheral vascular diseasecomparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Revascularisations for peripheral vascular disease comparing IL2 to placebo Number of revascularisations for peripheral vascular disease comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Amputations due to peripheral vascular disease comparing IL2 to placebo Number of amputations due to peripheral vascular disease comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Amputations due to peripheral vascular disease comparing IL2 to placebo Number of amputations due to peripheral vascular disease comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Amputations due to peripheral vascular disease comparing IL2 to placebo Number of amputations due to peripheral vascular disease comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Haemorrhagic strokes comparing IL2 to placebo Number of haemorrhagic strokes comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Haemorrhagic strokes comparing IL2 to placebo Number of haemorrhagic strokes comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Haemorrhagic strokes comparing IL2 to placebo Number of haemorrhagic strokes comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary New atrial fibrillation diagnosis comparing IL2 to placebo Number of new atrial fibrillation diagnoses comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary New atrial fibrillation diagnosis comparing IL2 to placebo Number of new atrial fibrillation diagnoses comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary New atrial fibrillation diagnosis comparing IL2 to placebo Number of new atrial fibrillation diagnoses comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
Secondary Ventricular arrhythmia (sustained ventricular tachycardia and ventricular fibrillation) comparing IL2 to placebo Number of ventricular arrhythmia episodes (sustained ventricular tachycardia and ventricular fibrillation) comparing IL2 to placebo 1 year from when initially dosed in preceding IVORY trial
Secondary Ventricular arrhythmia (sustained ventricular tachycardia and ventricular fibrillation) comparing IL2 to placebo Number of ventricular arrhythmia episodes (sustained ventricular tachycardia and ventricular fibrillation) comparing IL2 to placebo 2 years from when initially dosed in preceding IVORY trial
Secondary Ventricular arrhythmia (sustained ventricular tachycardia and ventricular fibrillation) comparing IL2 to placebo Number of ventricular arrhythmia episodes (sustained ventricular tachycardia and ventricular fibrillation) comparing IL2 to placebo 5 years from when initially dosed in preceding IVORY trial
See also
  Status Clinical Trial Phase
Completed NCT02552407 - Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis N/A
Completed NCT01398228 - Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3 N/A
Completed NCT01135667 - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI Phase 4
Recruiting NCT02592720 - Cocktail Injection Improves Outcomes of FFR Guided PCI Phase 4
Completed NCT01641510 - PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants Phase 3
Completed NCT01743274 - Does Optical Coherence Tomography Optimise Results of Stenting N/A
Active, not recruiting NCT01433627 - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX Phase 3
Completed NCT01452282 - Ankle-Brachial Index Estimating Cardiac Complications After Surgery N/A
Recruiting NCT01418794 - Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Phase 4
Recruiting NCT01000701 - Inflammation and Acute Coronary Syndromes N/A
Terminated NCT01107899 - Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes Phase 1
Completed NCT00494247 - Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes Phase 4
Terminated NCT00615719 - Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation N/A
Active, not recruiting NCT06089343 - High-risk Features of Coronary Lesions in CTA and OCT
Not yet recruiting NCT04023630 - DUAL Antithrombotic Therapy in Patients With AF and ACS Phase 4
Recruiting NCT02601404 - REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD) N/A
Completed NCT02195193 - Integrating Depression Care in Acute Coronary Syndromes Care in China N/A
Not yet recruiting NCT01735227 - Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Phase 4
Completed NCT02141750 - THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES N/A
Completed NCT00097591 - A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Phase 3